Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 7 sales; 333 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 25, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 28, 2022 |
| Operating expenses | $923.7M | $569.5M | $468.0M | $232.3M | $103.7M |
| Research and development | $794.3M | $476.6M | $332.3M | $169.5M | $78.4M |
| Selling, general and administrative | $129.4M | $92.9M | $60.7M | $39.8M | $25.3M |
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Interest expense | – | – | $0 | $2.00K | $7.00K |
| Income tax | $0 | – | – | – | – |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| EPS, basic | $-5.63 | $-3.80 | $-4.14 | $-3.44 | – |
| EPS, diluted | $-5.63 | $-3.80 | $-4.14 | $-3.44 | – |
| Weighted shares, basic | 136.1M | 122.0M | 97.2M | 64.9M | – |
| Weighted shares, diluted | 136.1M | 122.0M | 97.2M | 64.9M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 25, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 28, 2022 |
| Cash and equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M |
| Short-term investments | $1.39B | $1.36B | $682.8M | $96.7M | $177.0M |
| Total current assets | $1.63B | $1.79B | $1.10B | $942.6M | $256.3M |
| Property, plant and equipment | $257.4M | $198.0M | $79.6M | $10.4M | $7.95M |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.3M |
| Accounts payable | $70.9M | $48.5M | $14.6M | $9.79M | $6.76M |
| Total current liabilities | $205.8M | $140.2M | $145.3M | $40.5M | $28.7M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Shareholders' equity | $2.69B | $3.31B | $1.24B | $953.6M | $284.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 25, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 28, 2022 |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Capital expenditures | $13.7M | $22.4M | $16.1M | $5.85M | $6.55M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Depreciation and amortization | $16.4M | $7.00M | $3.16M | $2.58M | $1.80M |
| Stock-based compensation | $138.8M | $84.8M | $48.8M | $23.6M | $10.7M |
| Investing cash flow | $437.4M | -$2.01B | -$773.3M | $74.6M | -$212.3M |
| Financing cash flow | $2.01M | $2.45B | $639.8M | $861.5M | $17.8M |
| Net change in cash | -$213.8M | -$9.36M | -$437.0M | $765.7M | -$316.3M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 158.3M | +20.9% | SEC |
| Aug 3, 2026 | 148.8M | +14.6% | SEC |
| May 4, 2026 | 144.4M | +11.9% | SEC |
| Feb 20, 2026 | 143.9M | +11.8% | SEC |
| Oct 31, 2025 | 130.9M | +5.0% | SEC |
| Aug 4, 2025 | 129.8M | +16.3% | SEC |
| May 5, 2025 | 129.0M | +18.6% | SEC |
| Feb 21, 2025 | 128.8M | +18.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.